Major Biotech Licensing Deal
Hanmi Pharmaceutical Signs $2.3 Billion Obesity Drug Licensing Deal With Genentech
Key Points
Reported total deal value varies across outlets, with figures ranging from about 3.2 trillion won to 3.5 trillion won (and one listing 3.1723 trillion won). This discrepancy likely reflects differences in whether milestones are included and how exchange rates are applied.
This transaction is described as Hanmi’s largest-ever single-asset licensing deal and marks a major milestone for South Korea’s biotech export prowess, surpassing prior high-profile collaborations such as the 2015 Sanofi contract.
Genentech’s exclusive rights outside Korea and leadership of development from Phase 2 onward highlight Roche’s strategic push into non-GLP-1 obesity modalities and its potential to drive global commercialization if HM17321 proves successful.
The deal structure includes non-refundable upfront payments and milestone payments, with royalties post-launch, and protections for Hanmi if regulatory or clinical setbacks occur, with termination not triggering penalties.
Hanmi Pharmaceutical signed a landmark licensing deal with Genentech worth up to $2.3 billion for HM17321, a next-generation obesity drug candidate Seoul Daily. The agreement includes a $190 million upfront payment and milestone payments that could total around $2.1 billion, plus royalties after launch Korea Herald. This marks one of South Korea's largest-ever biotech licensing deals and signals Genentech's strategic shift away from the dominant GLP-1 obesity drugs toward a different mechanism.
HM17321 is a long-acting UCN2 analog that targets the CRF2 receptor, a different pathway than the GLP-1 treatments currently dominating the obesity market TipRanks. Hanmi emphasizes the drug's potential to help patients lose weight while preserving or even increasing lean muscle mass—a key advantage over GLP-1 therapies that sometimes reduce muscle along with fat BigGo Finance.
Genentech Takes Over Development After Phase 1
Hanmi will complete its current Phase 1 trial, then hand off leadership to Genentech starting in Phase 2 Seoul Daily. This structure lets Genentech, a Roche subsidiary, drive the expensive later-stage testing and eventual global commercialization outside South Korea Korea Herald. Hanmi retains rights in its home market and receives milestone payments tied to regulatory approvals and sales targets.
A Different Path in the Obesity Drug Race
Most obesity drugs today use the GLP-1 pathway—the mechanism behind Ozempic and Wegovy BigGo Finance. HM17321's UCN2 approach represents a bet on an alternative target that could work better for some patients TipRanks. Genentech's willingness to invest $2.3 billion signals confidence that CRF2 activation offers real clinical advantages in weight loss and muscle preservation.
Deal Structure Protects Hanmi if Development Fails
The agreement includes non-refundable upfront cash and milestone payments, not equity swaps Seoul Daily. If Genentech hits regulatory setbacks or clinical failures, the deal includes protections for Hanmi—it does not trigger penalty payments or reversions Korea Herald. This structure shifts risk to Genentech while guaranteeing Hanmi cash upfront regardless of outcomes.
Hanmi's Record Payday and South Korea's Biotech Moment
Hanmi's stock surged to its daily trading limit after the announcement Seoul Daily. The deal exceeds prior high-profile South Korean biotech collaborations, including Hanmi's own 2015 Sanofi partnership Korea Herald. It underscores a broader strategy by South Korean companies to monetize early-stage drug pipelines through partnerships with global pharma giants rather than fund all development independently.
Sentiment
Mostly PositivePublishers
13
Articles
45
Reach
58
